TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Bacterial clearance rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: PISQ score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of apnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Good outcome (achieved recovery and remained well)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fluctuating outcome (achieved recovery or remission but suffered a relapse or recurrence)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Poor outcome (remained depressed for the 6 months)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plasminogen activator inhibitor 1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Risk of developing skin cancer
Endpoint domain: Adverse events/effects
Primary endpoint: UVR exposure behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Perception of attractiveness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Lactate levels at reperfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: IMA levels at reperfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean reduction in PD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: REEDA scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Procedural success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Minimal luminal diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: peak VO2 during robotic treadmill walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: appetite loss
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: change in body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: BMI percentiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: endurance time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average absolute alcohol consumption during the first 6 weeks of pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of pregnant women consuming alcohol at levels likely to produce adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Level of anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physiological variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initial ED visit costs
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Total costs
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Reduction in Patient Health Questionnaire 9 (PHQ-9)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in SF-36 bodily pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: earlier remission of depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral glucose uptake (M value)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean irritative score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean obstructive score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urge incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: PEF (lowest % best)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of subjects with a symptom free day
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Best Corrected Visual Acuity (BCVA) at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Recurrence of vitreous haemorrhaging in the postoperative period
Endpoint domain: Adverse events/effects
Primary endpoint: SRT Consistent Long‐Term Retrieval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Visual memory (BVMT‐R Recall)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Bone mineral density (BMD) loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Castration levels of testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: reduced conflict around the birth decision
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Liver fibrosis indexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Mean Arterial Blood Pressure (MABP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: BMD level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge of caregivers
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Practice of caregivers
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Impaired cognitive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: local resectability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: length-for-age z scores (LAZs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of being stunted
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fine motor development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mullen Visual Reception scale gains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caldwell Home Observation for Measurement of the Environment scale improvement
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Quality of life of children with AOM
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Decrease in triacylglycerol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decrease in very LDL-C concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Objective akathisia scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antidepressant response to ketamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: poorer performance on tests of memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: poorer performance on tests of attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: risk of cognitive impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Histological disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improved functional performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGI-I score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieving at least 6mm in the shortest diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Holgers' Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensibility loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: poor outcome at completion of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: delayed neurological sequelae
Endpoint domain: Adverse events/effects
Primary endpoint: HPV positivity rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement between s-DRY and dr-WET samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Invalid results rate
Endpoint domain: Adverse events/effects
Primary endpoint: Abdominal circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: PEFR levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: IFN-gamma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: occurrence of postoperative AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: additional morphine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lowered arterial pressure to satisfactory levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 6-month successful rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year successful rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrent adenoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: adenomatous polyp burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: advanced recurrent adenoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Total leukocyte counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Eosinophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: poor functional outcome
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cancelled embryo transfer due to poor embryo development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of retrieved oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Fertilization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: MOCART scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with gel-based contraception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recommendation of method to others
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intention to use as primary method of contraception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: lower body dissatisfaction (BD)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean maximum increase in IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Response time during set-shifting and decision-making
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Responder rates at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: overall clinical improvement of pain status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean pain intensity decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of individuals reporting no depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incident rate of moderate-to-severe depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative temporal changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with treatment method
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Likelihood to recommend treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: additional life years
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of ESRD
Endpoint domain: Mortality/survival
Primary endpoint: Life years gained
Endpoint domain: Mortality/survival
Primary endpoint: ECW/ICW ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: leptin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Boston score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal volume increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasopharynx volume increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced leaflet motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Restoration of leaflet motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke/systemic embolism
Endpoint domain: Mortality/survival
Primary endpoint: Study drug discontinuation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: JP behaviour
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Arthritis Self-efficacy (ASES)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: JP self-efficacy (JP-SES)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: %CDT-positive rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet count of more than 20x10(9)/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Discontinuation of alprazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of study maintaining alprazolam-free status for 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dropout rate among panic disorder patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Bioavailability of lopinavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral clearance of lopinavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral clearance of ritonavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of peripheral neuropathy (PN)
Endpoint domain: Adverse events/effects
Primary endpoint: Time to PN onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reversibility of bortezomib-associated PN
Endpoint domain: Adverse events/effects
Primary endpoint: tourniquet pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to intraoperative analgesic rescue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immediate emergence (eye opening and extubation time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DRS scores on day 2 and 3 after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of hospital-based physicians' predictions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of reapplication
Endpoint domain: Adverse events/effects
Primary endpoint: NPSAE incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Time to resolution of rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence rate of rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung deposition (% total dose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral lung deposition (P:C ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Head and neck deposition (% total dose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Plaque Area (TPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Independent bladder control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraobserver agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of antibiotic treatment for sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in DAS28-erythrocyte sedimentation rate (ESR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with good/moderate EULAR responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of antidrug antibodies
Endpoint domain: Adverse events/effects
Primary endpoint: salivary cortisol response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Bone ingrowth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Bone contact
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: improved psychopathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Split jump flexibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IGA mod 2011 0/1 response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk score for falls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance with prevention behavior related to falls
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Self-efficacy for fall prevention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anatomic cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Point Ba measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: preterm birth
Endpoint domain: Mortality/survival
Primary endpoint: neonatal outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health-related quality of life (HRQoL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Health-related quality of life (HRQoL)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Health-related quality of life (HRQoL)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Willingness to perform bystander CPR
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Enzyme output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mean velocity of blood flow in the axillary and brachial arteries and veins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: maximum velocity of blood flow in the brachial artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety and tolerability of VLA84
Endpoint domain: Adverse events/effects
Primary endpoint: Immunogenicity (antibody titres against Toxin A and Toxin B)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Negative results to the HUT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistence at 1-year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: portion size of craved foods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of giving in to food cravings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain level measured by analogical visual scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-month gross cumulative pregnancy rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: discontinuation rates due to allergy
Endpoint domain: Adverse events/effects
Primary endpoint: discontinuation rate for other causes
Endpoint domain: Adverse events/effects
Primary endpoint: PASI percentage improvements from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage body surface area affected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Homeostasis model assessment of insulin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Energy deposition characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Risks of overheating
Endpoint domain: Adverse events/effects
Primary endpoint: Cognitive Failures Questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Squire Memory Complaint Questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Global Self‐Evaluation of Memory scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning